BCBenjamin D. Cons

Benjamin D. Cons

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Benjamin D. Cons has a total of 106 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Integrating fragment-based screening with targeted protein degradation and genetic rescue to explore eIF4E function

    by Swee Y. Sharp, Marianna Martella, Sabrina D’aGostino, Christopher I. Milton, George Ward, Andrew J. Woodhead, Caroline J. Richardson, Maria G. Carr, Elisabetta Chiarparin, Benjamin D. Cons, et al.

    Eukaryotic initiation factor 4E (eIF4E) serves as a regulatory hub for oncogene-driven protein synthesis and is considered a promising anticancer target. Here we screen a fragment library against eIF4E and identify a ligand-binding site with previously unknown function. Follow-up structure-based design yields a low nM tool compound (4, Kd = 0.09 µM; LE 0.38), which disrupts the eIF4E:eIF4G interaction, inhibits translation in cell lysates, and demonstrates target engagement with eIF4E in intact cells (EC50 = 2 µM). By coupling targeted protein degradation with genetic rescue using eIF4E mutants, we show that disruption of both the canonical eIF4G and non-canonical binding sites is likely required to drive a strong cellular effect. This work highlights the power of fragment-based drug discovery to identify pockets in difficult-to-drug proteins and how this approach can be combined with genetic characterization and degrader technology to probe protein function in complex biological systems.


  • Fragment-Based Discovery of a Series of Allosteric-Binding Site Modulators of β-Glucocerebrosidase

    by Nick Palmer, Christopher Agnew, Caroline Benn, William J. Buffham, Joan N. Castro, Gianni Chessari, Mellissa Clark, Benjamin D. Cons, Joseph E. Coyle, Lee A. Dawson, et al.

    Beta-Glucocerebrosidase (GBA/GCase) mutations leading to misfolded protein cause Gaucher's disease and are a major genetic risk factor for Parkinson's disease and dementia with Lewy bodies. The identification of small molecule pharmacological chaperones that can stabilize the misfolded protein and increase delivery of degradation-prone mutant GCase to the lysosome is a strategy under active investigation. Here, we describe the first use of fragment-based drug discovery (FBDD) to identify pharmacological chaperones of GCase. The fragment hits were identified by using X-ray crystallography and biophysical techniques. This work led to the discovery of a series of compounds that bind GCase with nM potency and positively modulate GCase activity in cells.


  • Open Access

    Alkene 1,3‐Difluorination via Transient Oxonium Intermediates

    by Alice C. Dean, E. Harvey Randle, Andrew J. D. Lacey, Guilherme A. Marczak Giorio, Sayad Doobary, Benjamin D. Cons, Alastair J. J. Lennox

    The 1,3‐difunctionalization of unactivated alkenes is an under‐explored transformation that leads to moieties that are otherwise challenging to prepare. Herein, we report a hypervalent iodine‐mediated 1,3‐difluorination of homoallylic (aryl) ethers to give unreported 1,3‐difluoro‐4‐oxy groups with moderate to excellent diastereoselectivity. The transformation proceeds through a different mode of reactivity for 1,3‐difunctionalization, in which a regioselective addition of fluoride opens a transiently formed oxonium intermediate to rearrange an alkyl chain. The optimized protocol is scalable and shown to proceed well with a variety of functional groups and substitution on the alkenyl chain, hence providing ready access to this fluorinated, conformationally controlled moiety.

  • Open Access

    Alkene 1,3‐Difluorination via Transient Oxonium Intermediates

    by Alice C. Dean, E. Harvey Randle, Andrew J. D. Lacey, Guilherme A. Marczak Giorio, Sayad Doobary, Benjamin D. Cons, Alastair J. J. Lennox

    The 1,3‐difunctionalization of unactivated alkenes is an under‐explored transformation that leads to moieties that are otherwise challenging to prepare. Herein, we report a hypervalent iodine‐mediated 1,3‐difluorination of homoallylic (aryl) ethers to give unreported 1,3‐difluoro‐4‐oxy groups with moderate to excellent diastereoselectivity. The transformation proceeds through a different mode of reactivity for 1,3‐difunctionalization, in which a regioselective addition of fluoride opens a transiently formed oxonium intermediate to rearrange an alkyl chain. The optimized protocol is scalable and shown to proceed well with a variety of functional groups and substitution on the alkenyl chain, hence providing ready access to this fluorinated, conformationally controlled moiety.


  • Enabling synthesis in fragment-based drug discovery (FBDD): microscale high-throughput optimisation of the medicinal chemist's toolbox reactions

    by Chloe Townley, Davide Branduardi, Gianni Chessari, Benjamin D. Cons, Charlotte Griffiths-Jones, Richard J. Hall, Christopher N. Johnson, Yuji Ochi, Stuart Whibley, Rachel Grainger

    Democratised high-throughput experimentation for FBDD.


  • X-ray Screening of an Electrophilic Fragment Library and Application toward the Development of a Novel ERK 1/2 Covalent Inhibitor

    by Jeffrey D. St. Denis, Gianni Chessari, Anne Cleasby, Benjamin D. Cons, Suzanna Cowan, Samuel E. Dalton, Charlotte East, Christopher W. Murray, Marc O’rEilly, Torren Peakman, et al.

    Fragment-based drug discovery (FBDD) has become an established method for the identification of efficient starting points for drug discovery programs. In recent years, electrophilic fragment screening has garnered increased attention from both academia and industry to identify novel covalent hits for tool compound or drug development against challenging drug targets. Herein, we describe the design and characterization of an acrylamide-focused electrophilic fragment library and screening campaign against extracellular signal-regulated kinase 2 (ERK2) using high-throughput protein crystallography as the primary hit-finding technology. Several fragments were found to have covalently modified the adenosine triphosphate (ATP) binding pocket Cys166 residue. From these hits, 22, a covalent ATP-competitive inhibitor with improved potency (ERK2 IC50 = 7.8 μM), was developed.


  • Fragment-Based Discovery of a Novel, Brain Penetrant, Orally Active HDAC2 Inhibitor

    by Emiliano Tamanini, Shin Miyamura, Ildiko M. Buck, Benjamin D. Cons, Lee Dawson, Charlotte East, Takashi Futamura, Shintaro Goto, Charlotte Griffiths-Jones, Tetsuya Hashimoto, et al.

    Fragment-based ligand discovery was successfully applied to histone deacetylase HDAC2. In addition to the anticipated hydroxamic acid-and benzamide-based fragment screening hits, a low affinity (similar to 1 mM) alpha-amino-amide zinc binding fragment was identified, as well as fragments binding to other regions of the catalytic site. This alternative zinc-binding fragment was further optimized, guided by the structural information from protein-ligand complex X-ray structures, into a sub-mu M, brain HDAC2 inhibitor (17) of histone levels in vivo.


  • Electrostatic Complementarity in Structure-Based Drug Design

    by Benjamin D. Cons, David G. Twigg, Rajendra Kumar, Gianni Chessari

    Optimization of electrostatic complementarity is an important strategy in structure-based drug discovery for improving the affinity of molecules against a specific protein target. In this Miniperspective we identify examples where deliberate optimization of protein-ligand electrostatic complementarity or intramolecular electrostatic interactions gave improvements in target affinity (up to 250-fold), physicochemical properties, in vitro properties, and off-target selectivity. We also look retrospectively at a series of factor Xa inhibitors that show an almost 8000-fold range in potency that can be correlated with the calculated electrostatic potential (ESP) surfaces. Recent developments using a graph-convolutional deep neural network to rapidly generate high quality ESP surfaces have the potential to make this useful tool more accessible for a wider audience within the field of medicinal chemistry.


  • Open Access

    Fragment-based drug discovery and its application to challenging drug targets

    by Amanda J Price, Steven Howard, Benjamin D Cons

    Fragment-based drug discovery (FBDD) is a technique for identifying low molecular weight chemical starting points for drug discovery. Since its inception 20 years ago, FBDD has grown in popularity to the point where it is now an established technique in industry and academia. The approach involves the biophysical screening of proteins against collections of low molecular weight compounds (fragments). Although fragments bind to proteins with relatively low affinity, they form efficient, high quality binding interactions with the protein architecture as they have to overcome a significant entropy barrier to bind. Of the biophysical methods available for fragment screening, X-ray protein crystallography is one of the most sensitive and least prone to false positives. It also provides detailed structural information of the protein–fragment complex at the atomic level. Fragment-based screening using X-ray crystallography is therefore an efficient method for identifying binding hotspots on proteins, which can then be exploited by chemists and biologists for the discovery of new drugs. The use of FBDD is illustrated here with a recently published case study of a drug discovery programme targeting the challenging protein–protein interaction Kelch-like ECH-associated protein 1:nuclear factor erythroid 2-related factor 2.


  • Bicyclic Oxygen Heterocycles from γ,δ-Unsaturated Alcohols: Synthetic Targets Inspired by Blepharocalyxin D

    by Adam J. Bunt, Christopher D. Bailey, Benjamin D. Cons, Sophie J. Edwards, Jon D. Elsworth, Tshepo Pheko, Christine L. Willis